Precise Bio, a North Carolina-based regenerative medicine company, announced the launch of a dedicated ophthalmic business unit at its Winston-Salem plant. Established health care companies have established strategic partnerships to advance the research on the biological 3D printing of the cornea of the eye and bring it to market.
Precise Bio has developed an innovative 4D biomanufacturing technology that includes cell expansion, biomaterials, processes, and printing technologies. The main advantages of this platform over other biomanufacturing methods are the ability to generate complex organizations in a highly repeatable way and to apply the lessons learned from the manufacture of one organization to the next. The platform can address the key limitations of existing 3D bioprinting technologies and lay the foundation for the engineering design of more complex tissues and organs.
Precise Bio has transplanted biological 3D printed artificial cornea into animals. Preliminary research results have proved the feasibility, safety and effectiveness of Precise Bio's new technology, which has laid the foundation for the development and progress of future human experiments. In addition to developing 3D printed artificial corneas, the company is also developing other tissues and devices for ophthalmic indications, including retinal patches, vision correction microlenses, and more.
Precise Bio's 4D biomanufacturing platform with its proprietary laser-assisted bioprinting technology